Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Jan Rehwinkel, a group leader in the MRC Human Immunology Unit, who was named last week as one of 25 new EMBO Young Investigators.

Jan Rehwinkel 2016

Professor Rehwinkel joins a network of 74 current and 382 past Young Investigators who represent some of the best young group leaders in the life sciences in Europe and beyond.

“The EMBO Young Investigator Programme supports young life scientists in their most demanding career phase, when they establish their own research group,” says Maria Leptin, EMBO Director. “Each of the successful candidates has shown great potential to deliver world-class research, and we look forward to supporting them.”

The Young Investigator Programme provides support for researchers under forty years of age who have set up their first laboratories in the past four years. During their three-year tenure, EMBO Young Investigators receive a range of benefits, including an award of 15,000 euros and the opportunity to apply for additional funds to support the establishment of their first independent laboratories.

Laboratory management and non-scientific skills training as well as PhD courses offer the young group leaders and their students the chance to develop professional skills. The scientists also receive access to core facilities at EMBL and funding for themselves and their group members to attend conferences.

This year the programme received 211 applications, and 12 per cent of the candidates who applied were selected.

The next application deadline is 1 April 2017. More information can be found at http://www.embo.org/funding-awards/young-investigators

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.